Fidelity Investments
SMMT icon

Fidelity Investments’s Summit Therapeutics SMMT Stock Holding History

Fidelity Investments’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$146M Sell
10,043,947
-809,252
-7% -$14.4M 0.01% 1070
2026
Q1 		$206M Sell
10,853,199
-2,507,608
-19% -$40.6M 0.01% 837
2025
Q4 		$234M Buy
13,360,807
+4,442,920
+50% +$83.6M 0.01% 803
2025
Q3 		$184M Sell
8,917,887
-308,489
-3% -$7.48M 0.01% 882
2025
Q2 		$196M Sell
9,226,376
-111,847
-1% -$2.55M 0.01% 827
2025
Q1 		$180M Buy
9,338,223
+1,282,853
+16% +$25.7M 0.01% 832
2024
Q4 		$144M Sell
8,055,370
-247,749
-3% -$4.8M 0.01% 967
2024
Q3 		$182M Buy
8,303,119
+737,692
+10% +$10.3M 0.01% 855
2024
Q2 		$59M Sell
7,565,427
-409,104
-5% -$2.21M ﹤0.01% 1251
2024
Q1 		$33M Buy
7,974,531
+7,965,209
+85,445% +$31.7M ﹤0.01% 1481
2023
Q4 		$24.3K Buy
9,322
+6,233
+202% +$12.8K ﹤0.01% 3840
2023
Q3 		$5.78K Buy
3,089
+2,464
+394% +$4.7K ﹤0.01% 4295
2023
Q2 		$1.57K Buy
+625
New +$1.14K ﹤0.01% 4647
2022
Q2 		– Sell
-729
Closed -$2K – 5432
2022
Q1 		$2K Buy
+729
New +$1.84K ﹤0.01% 4703

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments's SMMT Position: Q2 2026 in Review

Fidelity Investments reduced its Summit Therapeutics (SMMT) stake by 7.5% in Q2 2026, selling an estimated $14.4M and leaving 10,043,947 shares worth $146M. The position accounts for 0.01% of the portfolio, ranked #1070.

Fidelity Investments first reported a position in SMMT in Q1 2022 and has held it in 14 quarters since. The position peaked at $234M in Q4 2025. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Fidelity Investments held 10,043,947 shares of Summit Therapeutics worth $146M as of Q2 2026.
  • Fidelity Investments sold 809,252 Summit Therapeutics shares in Q2 2026, an estimated $14.4M.
  • Summit Therapeutics made up 0.01% of Fidelity Investments's portfolio in Q2 2026, its #1070 holding.
  • Fidelity Investments first reported a position in Summit Therapeutics in Q1 2022 and has held it in 14 quarters since.
  • Fidelity Investments's Summit Therapeutics position peaked at $234M in Q4 2025.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.